Haemonetics Corporation (HAE) AI Stock Analysis
HAE AI stock analysis summary
AI ResearchHaemonetics Corporation (NYSE: HAE) is a medical devices provider serving the plasma, blood center, and hospital markets. Over the trailing twelve months, the company generated $1.35B in revenue with an operating margin of 17.9%. The stock has appreciated 137.7% over the past year, trading at a forward P/E of 20.3x.
- Market cap
- $5.38B
- Revenue (TTM)
- $1.35B
- P/E
- 57.1x fwd 20.3x
- 1Y return
- 137.7% S&P 500 16.8%
- Avg. target
- $124.50 5.3% vs last close
Bull case
- Operating cash flow reached $293.2M in FY2026, funding $260.4M in free cash flow.
- Operating margin improved to 17.9% on a trailing twelve-month basis, exceeding the US-listed Healthcare peer median of 14.0%.
- The company reduced its 5-year share count by 11.0%, supported by $175.0M in share repurchases in FY2026.
Bear case
- Annual revenue fell 2.0% in FY2026 to $1.33B, down from $1.36B in FY2025.
- Net income declined from $167.7M in FY2025 to $97.3M in FY2026, lowering net margin to 7.3%.
- Total debt of $1.17B exceeds cash reserves of $223.4M, resulting in net debt of $950.8M.
What Haemonetics does
Haemonetics Corporation provides medical products and solutions across three segments: Plasma, Blood Center, and Hospital. Its Plasma segment provides automated plasma collection devices, disposables, and software such as NexSys PCS, PCS2, and the NexLynk DMS donor management system. The Blood Center segment offers automated blood component systems including MCS apheresis equipment, manual whole blood collection sets, storage solutions, SafeTrace Tx blood bank information systems, and BloodTrack blood management software. The Hospital segment provides hemostasis analyzer systems including TEG, ClotPro, and HAS to assist clinicians with medical procedures.
Growth and profitability
Haemonetics delivered a 5-year revenue CAGR of 8.9% from FY2021 to FY2026. Annual revenue grew from $993.2M in FY2022 to $1.36B in FY2025, before declining 2.0% to $1.33B in FY2026. Gross margin stood at 55.7% in FY2026, while operating margin expanded to 18.1%. Net income in FY2026 was $97.3M, yielding an EPS of $4.97. In the latest quarter ended June 30, 2026, quarterly revenue increased 5.6% year-over-year, while quarterly earnings rose 2.9%, supporting trailing twelve-month revenue of $1.35B and a profit margin of 7.1%.
Balance sheet and cash flow
As of June 30, 2026, Haemonetics held $223.4M in cash and short-term investments against total debt of $1.17B, resulting in net debt of $950.8M. Shareholders' equity was $837.1M, with a current ratio of 3.08 and a debt-to-equity ratio of 1.40. In FY2026, the company generated operating cash flow of $293.2M and free cash flow of $260.4M. Capital expenditures were $32.8M, and share buybacks totaled $175.0M, contributing to an 11.0% reduction in share count over 5 years.
Valuation and performance
Haemonetics carries a market capitalization of $5.38B and an enterprise value of $5.81B. The stock trades at a trailing P/E of 57.1x and a forward P/E of 20.3x, compared to the median of its US-listed Healthcare peers of 24.6x trailing and 17.3x forward. Its EV/EBITDA of 9.4x sits below the peer median of 12.0x, while its price-to-sales of 4.0x aligns closely with the peer median of 4.1x. Over the past year, HAE gained 137.7%, outperforming the SPY return of 16.8%, while its 5-year gain of 69.2% trails SPY's 83.0%.
What analysts expect
Wall Street coverage includes 5 Strong Buy, 4 Buy, and 2 Hold ratings, with zero Sell or Strong Sell recommendations. The mean price target is $124.50, representing a 5.3% upside compared to the October 16, 2026 closing price of $118.28. Consensus estimates forecast FY2027 revenue of $1.42B and EPS of $5.31, representing 7.0% earnings growth. Haemonetics has beaten EPS estimates in each of the last 4 quarters, with its next earnings release scheduled for November 5, 2026.
Key risks and what to watch
- Total debt of $1.17B creates a debt-to-equity ratio of 1.40 that requires steady cash generation to service.
- The stock trades 54.1% above its 200-day moving average and near its 52-week high of $123.77, leaving little room for operational missteps.
- Short interest sits at 7.8% of float, indicating lingering skepticism from market participants.
- Net margin compressed to 7.1% over the trailing twelve months, down from 12.3% in FY2025.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this HAE AI stock analysis
This page is an AI-written research summary of Haemonetics Corporation (HAE). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: HAE income statement, HAE balance sheet, HAE key metrics, HAE analyst forecast, HAE chart. See the HAE stock overview for the latest quote and news.
HAE AI stock analysis FAQ
What is Haemonetics Corporation's core business?
Haemonetics manufactures medical devices and disposables across three segments: Plasma, Blood Center, and Hospital, including apheresis systems, donor management software, and hemostasis analyzers.
Does Haemonetics pay a dividend?
No, Haemonetics does not currently pay a dividend, focusing its capital allocation on internal investments and share buybacks such as the $175.0M repurchased in FY2026.
What is the consensus analyst price target for HAE?
The mean analyst price target is $124.50, which is 5.3% above the October 16, 2026 closing price of $118.28.
When does Haemonetics report its next quarterly results?
Haemonetics Corporation is scheduled to report its next financial results on November 5, 2026.